Rivaroxaban: Expanded Role in Cardiovascular Disease Management—A Literature Review

<table class="table-group" id="tab1"><tr><td><table class="table"><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr class="thead"><td class="align_left">Indication</td><td class="align_center">Year of approval</td><td class="align_center">Country</td></tr><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr><td class="align_left">DVT/PE prophylaxis in hip and knee surgery</td><td class="align_center">2008 in Europe<br/>2011 in USA</td><td class="align_left"></td></tr><tr><td class="align_left">Atrial fibrillation</td><td class="align_center">2011</td><td class="align_center">USA and Europe</td></tr><tr><td class="align_left">DVT/PE treatment</td><td class="align_center">2012</td><td class="align_center">USA and Europe</td></tr><tr><td class="align_left">Acute coronary syndrome</td><td class="align_center">2013</td><td class="align_center">Europe</td></tr><tr><td class="align_left">To reduce risk of VTE after 6 months of treatment of DVT/PE</td><td class="align_center">2017</td><td class="align_center">USA and Europe</td></tr><tr><td class="align_left">Stable CAD</td><td class="align_center">2018</td><td class="align_center">USA and Europe</td></tr><tr><td class="align_left">PAD</td><td class="align_center">2018</td><td class="align_center">USA and Europe</td></tr><tr><td class="align_left">DVT/PE prophylaxis in acute medical illness</td><td class="align_center">2019</td><td class="align_center">USA</td></tr><tr class="table-tr"><td colspan="3"><hr class="tbody-hr"/></td></tr></table></td></tr><tr class="table-fn"><td><div>DVT/PE: deep vein thrombosis/pulmonary embolism; CAD: coronary artery disease; PAD: peripheral arterial disease.<br/></div></td></tr></table>

<div>Indications and approval of rivaroxaban.</div>

Cardiovascular Therapeutics

tab1

Table 1

Table 1: Rivaroxaban: Expanded Role in Cardiovascular Disease Management—A Literature Review 